Arvinas. has been granted a patent for bifunctional compounds that modulate LRRK2 by linking it to cereblon E3 ubiquitin ligase, facilitating target protein degradation. These compounds may treat or prevent diseases linked to improper regulation of LRRK2. GlobalData’s report on Arvinas gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arvinas, Cancer treatment biomarkers was a key innovation area identified from patents. Arvinas's grant share as of July 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Bifunctional compounds for targeting and degrading lrrk2 protein
The granted patent US12053469B2 outlines several claims related to a specific compound and its pharmaceutical applications. The first claim identifies a compound selected from a defined group, which serves as the foundation for subsequent claims. The second claim expands on this by describing a pharmaceutical composition that includes the identified compound along with a pharmaceutically acceptable carrier. Further claims detail the potential for this composition to incorporate an additional bioactive agent, which may include anti-inflammatory, chemotherapy, or immunomodulatory agents, enhancing the therapeutic efficacy of the primary compound.
Additionally, the patent specifies that the pharmaceutical composition can be utilized for treating diseases or disorders associated with the LRRK2 gene in subjects. Claim five emphasizes the relevance of this composition in addressing conditions such as idiopathic Parkinson's disease, LRRK2 mutation-associated Parkinson's disease, primary tauopathies, Lewy body dementia, Crohn's Disease, Leprosy, and neuroinflammation. This highlights the potential therapeutic applications of the compound in a range of neurodegenerative and inflammatory disorders, indicating its significance in the development of targeted treatments for these conditions.
To know more about GlobalData’s detailed insights on Arvinas, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
